NasdaqCM - Delayed Quote USD

ZyVersa Therapeutics, Inc. (ZVSA)

0.6075 -0.0025 (-0.41%)
At close: April 25 at 4:00 PM EDT
0.6100 +0.00 (+0.41%)
After hours: April 25 at 7:49 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ZVSA

Recent News: ZVSA

View More
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
GlobeNewswire 21 days ago
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire last month
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
GlobeNewswire last month
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
GlobeNewswire last month
ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity

ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity
GlobeNewswire last month
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications

ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
GlobeNewswire last month
ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option

ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
GlobeNewswire 2 months ago
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases

ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
GlobeNewswire 2 months ago
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones

ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones
GlobeNewswire 2 months ago
ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes

ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes
GlobeNewswire 2 months ago
ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease

ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease
GlobeNewswire 2 months ago
Why Is Inflammatory Disease-Focused ZyVersa Therapeutics Stock Trading Higher Today?

Why Is Inflammatory Disease-Focused ZyVersa Therapeutics Stock Trading Higher Today?
Benzinga 3 months ago
View More

Related Tickers

RNAZ TransCode Therapeutics, Inc.
0.5250
+19.35%
 
ENSC Ensysce Biosciences, Inc.
0.5467
-2.13%
 
SPRC SciSparc Ltd.
1.2600
+4.13%
 
PBLA Panbela Therapeutics, Inc.
0.4400
+7.29%
 
TCBP TC Biopharm (Holdings) Plc
1.5700
+6.80%
 
PXMD PaxMedica, Inc.
0.7042
+1.76%
 
CDIO Cardio Diagnostics Holdings, Inc.
0.7224
-3.68%
 
ATXI Avenue Therapeutics, Inc.
0.1170
+24.07%
 
ALLR Allarity Therapeutics, Inc.
1.4300
+4.38%
 
REVB Revelation Biosciences, Inc.
2.1399
+2.39%